Table 4.
The clinical outcome of study group (hsPDA) compared with comparison groups.
| hsPDA | Nonsignificant PDA | p value | No PDA | p value | |
|---|---|---|---|---|---|
| Length of mechanical | 24 ± 21.7 | 5.1 ± 11.2 | 0.03 | 3 ± 6.4 | 0.01 |
| ventilation (days) | |||||
| Length of nasal sup. (days) | 48.7 ± 60.2 | 21.6 ± 18 | 0.19 | 14.5 ± 17 | 0.11 |
| Length of O2 (days) | 65.5 ± 70.3 | 21.8 ± 27.3 | 0.09 | 12.7 ± 15.2 | 0.04 |
| Length of stay (days) | 92.6 ± 70.4 | 70.7 ± 26.9 | 0.37 | 64.8 ± 40.7 | 0.27 |
| IVH/PVL* | 6 (46%) | 1 (8%) | 0.07 | 1 (5%) | 0.02 |
| NEC* | 5 (38%) | 2 (17%) | 0.40 | 2 (11%) | 0.09 |
| ROP* | 0 | 1 (8%) | 1 | 0 | 1 |
| BPD* | 9 (69%) | 2 (17%) | 0.02 | 5 (28%) | 0.05 |
*Data presented as mean ± SD, Two-sample T-Test. Data with asterisk (*) presented as number of infants(percent), analyzed with Chi-square test and Fisher Exact test.
Nasal sup. nasal support, O2 oxygen, IVH/PVL intraventricular hemorrhage/periventricular leukomalacia, NEC necrotizing enterocolitis, ROP retinopathy of prematurity, BPD bronchopulmonary dysplasia.
Statistically significant p-values are in bold.